Casper Pharma receives EIR from USFDA for its PAI
The inspection concluded with no observation (FDA-483) issued.
The inspection concluded with no observation (FDA-483) issued.
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
Subscribe To Our Newsletter & Stay Updated